Sodium-glucose co-transporter 2 inhibition and acute myocardial infarction: the DAPA-MI and EMPACT-MI trials

REFERENCES

• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757–1780. doi:10.1016/j.jacc.2021.12.011
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Vahl TP, Goliasch G, et al. Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion. Circulation. 2016;133(10):954–966. doi:10.1161/CIRCULATIONAHA.115.012427
   PubMed Web of Science ®Google Scholar
• Zaman MA, Kalsoom S, Koran W. CSL112 and HDL function hypothesis - a never-ending wait. Expert Rev Clin Pharmacol. Published online July 15, 2024. doi:10.1080/17512433.2024.2378763
   Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117–127. doi:10.1056/NEJMoa2204233
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. doi:10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960. doi:10.1038/s41591-021-01536-x
   PubMed Web of Science ®Google Scholar
• Paolisso P, Bergamaschi L, Gragnano F, et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res. 2023;187:106597. doi:10.1016/j.phrs.2022.106597
   PubMed Web of Science ®Google Scholar
• James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. doi:10.1056/EVIDoa2300286
   PubMedGoogle Scholar
• Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455–1466. doi:10.1056/NEJMoa2314051
   PubMed Web of Science ®Google Scholar
• Dominguez Rieg JA, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes Metab. 2019;2 1 Suppl 2(Suppl 2):43–52. doi:10.1111/dom.13630
   Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129–139. doi:10.1056/NEJMoa2030186
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033] [published correction appears in Circulation. 2022 Sep 27;146(13):e185] [published correction appears in Circulation. 2023 Apr 4;147(14):e674]. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117–128. doi:10.1056/NEJMoa2030183
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Shimoda M, Sanada J, et al. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study. Diabetes Ther. 2018;9(4):1569–1580. doi:10.1007/s13300-018-0447-8
   PubMed Web of Science ®Google Scholar
• Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. Ther Adv Endocrinol Metab. 2022;13:20420188221090001. Published 2022 Apr 13. doi:10.1177/20420188221090001
   Web of Science ®Google Scholar
• Jasleen B, Vishal GK, Sameera M, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023;15(1):e33939. Published 2023 Jan 18. doi:10.7759/cureus.33939
   PubMed Web of Science ®Google Scholar
• Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. Published 2023 Apr 6. doi:10.1136/bmj-2022-074068
   PubMedGoogle Scholar
• Costantino S, Akhmedov A, Melina G, et al. Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. Eur Heart J. 2019;40(12):997–1008. doi: 10.1093/eurheartj/ehy903
   PubMed Web of Science ®Google Scholar
• Hussain S, Khan AW, Akhmedov A, et al. Hyperglycemia induces myocardial dysfunction via epigenetic regulation of JunD. Circ Res. 2020;127(10):1261–1273. doi: 10.1161/CIRCRESAHA.120.317132
   PubMed Web of Science ®Google Scholar
• Marfella R, D’Onofrio N, Trotta MC, et al. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2022;127:154936. doi:10.1016/j.metabol.2021.154936
   PubMed Web of Science ®Google Scholar
• Sardu C, Gatta G, Pieretti G, et al. SGLT2 breast expression could affect the cardiovascular performance in pre-menopausal women with fatty vs. non fatty breast via over-inflammation and sirtuins’ down regulation. Eur J Intern Med. 2023;113:57–68. doi:10.1016/j.ejim.2023.04.012
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Mayr M, Badimon J. SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism. Circulation. 2022;146(11):819–821. doi: 10.1161/CIRCULATIONAHA.122.060805
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Requena-Ibáñez JA, Picatoste B, et al. Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. Circ Cardiovasc Imaging. 2023;16(4):e015298. doi:10.1161/CIRCIMAGING.123.015298
   PubMed Web of Science ®Google Scholar
• Paolisso P, Bergamaschi L, Santulli G, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77. Published 2022 May 15. doi:10.1186/s12933-022-01506-8
   PubMed Web of Science ®Google Scholar
• Sardu C, Massetti M, Testa N, et al. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Front Pharmacol. 2021;12:777083. Published 2021 Nov 15. doi:10.3389/fphar.2021.777083
   PubMed Web of Science ®Google Scholar
• Sardu C, Trotta MC, Sasso FC, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22(1):80. Published 2023 Apr 1. doi:10.1186/s12933-023-01814-7
   PubMed Web of Science ®Google Scholar
• Marfella R, Sardu C, D’Onofrio N, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21(1):71. Published 2023 Feb 24. doi:10.1186/s12916-023-02781-2
   PubMed Web of Science ®Google Scholar
• Sardu C, Massimo Massetti M, Rambaldi P, et al. SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. Metabolism. 2022;137:155243. doi:10.1016/j.metabol.2022.155243
   PubMedGoogle Scholar
• von Lewinski D, Kolesnik E, Tripolt NJ, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43:4421–32. doi:10.1093/eurheartj/ehac494
   PubMedGoogle Scholar